Chun-Mei Hu

Chun-Mei Hu

Auto-generated profile, based on publicly available information

Chun-Mei Hu

Genomics Research Center, Academia Sinica, Taipei, 115201, Taiwan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Cell Metabolism
Verified
Journal Article
Closed access
CHChun-Mei Hu
Chun-Mei Hu
STSui-Chih Tien
Sui-Chih Tien
PHPing-Kun Hsieh
Ping-Kun Hsieh
YJYung-Ming Jeng
Yung-Ming Jeng
MCMing-Chu Chang
Ming-Chu Chang
WLWen-Hwa Lee
Wen-Hwa Lee

24 September 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YLYu-Huei Liu
Yu-Huei Liu
CHChun-Mei Hu
Chun-Mei Hu
YHYuan-Sheng Hsu
Yuan-Sheng Hsu
WLWen-Hwa Lee
Wen-Hwa Lee
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide. The primary reasons for this are the lack of early detection methods and targeted therapy. Emerging evidence highlights the metabolic addiction of cancer cells as a potential target to combat PDAC. Oncogenic mutations ofKRASare the most common triggers that drive glucose uptake and utilization via metabolic reprogramming to support PDAC growth. Conversely, high glucose levels in the pancreatic microenvironment trigger genome instability andde novomutations, includingKRASG12D, in pancreatic cells through metabolic reprogramming. Here, we review convergent and diverse metabolic networks related to oncogenicKRASmutations between PDAC initiation and progression, emphasizing the interplay among oncogenic mutations, glucose metabolic reprogramming, and the tumor microenvironment. Recognizing cancer-related glucose metabolism will provide a better strategy to prevent and treat the high risk PDAC population.

29 November 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JHJye-Lin Hsu
Jye-Lin Hsu
JCJen‐Wei Chou
Jen‐Wei Chou
TCTzu‐Fan Chen
Tzu‐Fan Chen
JHJeh‐Ting Hsu
Jeh‐Ting Hsu
FSFang‐Yi Su
Fang‐Yi Su
WLWen‐Hwa Lee
Wen‐Hwa Lee
Human caspase‐4 and its mouse homolog caspase‐11 are receptors for cytoplasmic lipopolysaccharide. Activation of the caspase‐4/11‐dependent NLRP3 inflammasome is required for innate defense and endotoxic shock, but how caspase‐4/11 is modulated remains unclear. Here, we show that mice lacking the oxidative stress sensor glutathione peroxidase 8 (GPx8) are more susceptible to colitis and endotoxic shock, and exhibit reduced richness and diversity of the gut microbiome. C57BL/6 mice that underwent adoptive cell transfer of GPx8‐deficient macrophages displayed a similar phenotype of enhanced colitis, indicating a critical role of GPx8 in macrophages. GPx8 binds covalently to caspase‐4/11 via disulfide bonding between cysteine 79 of GPx8 and cysteine 118 of caspase‐4 and thus restrains caspase‐4/11 activation, while GPx8 deficiency leads to caspase‐4/11‐induced inflammation during colitis and septic shock. Inhibition of caspase‐4/11 activation with small molecules reduces the severity of colitis in GPx8‐deficient mice. Notably, colonic tissues from patients with ulcerative colitis display low levels of Gpx8 and high caspase‐4 expression. In conclusion, these results suggest that GPx8 protects against colitis by negatively regulating caspase‐4/11 activity.

26 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYi-Ing Chen
Yi-Ing Chen
CCChin-Chun Chang
Chin-Chun Chang
MHMin-Fen Hsu
Min-Fen Hsu
YJYung-Ming Jeng
Yung-Ming Jeng
YTYu-Wen Tien
Yu-Wen Tien
WLWen-Hwa Lee
Wen-Hwa Lee
Tumor cells with diverse phenotypes and biological behaviors are influenced by stromal cells through secretory factors or direct cell-cell contact. Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive desmoplasia with fibroblasts as the major cell type. In the present study, we observe enrichment of myofibroblasts in a juxta-tumoral position with tumor cells undergoing epithelial-mesenchymal transition (EMT) that facilitates invasion and correlates with a worse clinical prognosis in PDAC patients. Direct cell-cell contacts forming heterocellular aggregates between fibroblasts and tumor cells are detected in primary pancreatic tumors and circulating tumor microemboli (CTM). Mechanistically, ATP1A1 overexpressed in tumor cells binds to and reorganizes ATP1A1 of fibroblasts that induces calcium oscillations, NF-κB activation, and activin A secretion. Silencing ATP1A1 expression or neutralizing activin A secretion suppress tumor invasion and colonization. Taken together, these results elucidate the direct interplay between tumor cells and bound fibroblasts in PDAC progression, thereby providing potential therapeutic opportunities for inhibiting metastasis by interfering with these cell-cell interactions.

3 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HWHeng-Hsiung Wu
Heng-Hsiung Wu
LTLung-Hung Tsai
Lung-Hung Tsai
CHChun-Kai Huang
Chun-Kai Huang
PHPang-Hung Hsu
Pang-Hung Hsu
MCMei-Yu Chen
Mei-Yu Chen
WLWen-Hwa Lee
Wen-Hwa Lee
The members of the interleukin-17 (IL-17) cytokine family and their receptors were identified decades ago. Unlike IL-17 receptor A (IL-17RA), which heterodimerizes with IL-17RB, IL-17RC, and IL-17RD and mediates proinflammatory gene expression, IL-17RB plays a distinct role in promoting tumor growth and metastasis upon stimulation with IL-17B. However, the molecular basis by which IL-17RB promotes oncogenesis is unknown. Here, we report that IL-17RB forms a homodimer and recruits mixed-lineage kinase 4 (MLK4), a dual kinase, to phosphorylate it at tyrosine-447 upon treatment with IL-17B in vitro. Higher amounts of phosphorylated IL-17RB in tumor specimens obtained from patients with pancreatic cancer correlated with worse prognosis. Phosphorylated IL-17RB recruits the ubiquitin ligase tripartite motif containing 56 to add lysine-63–linked ubiquitin chains to lysine-470 of IL-17RB, which further assembles NF-κB activator 1 (ACT1) and other factors to propagate downstream oncogenic signaling. Consequentially, IL-17RB mutants with substitution at either tyrosine-447 or lysine-470 lose their oncogenic activity. Treatment with a peptide consisting of amino acids 403 to 416 of IL-17RB blocks MLK4 binding, tyrosine-477 phosphorylation, and lysine-470 ubiquitination in vivo, thereby inhibiting tumorigenesis and metastasis and prolonging the life span of mice bearing pancreatic tumors. These results establish a clear pathway of how proximal signaling of IL-17RB occurs and provides insight into how this pathway provides a therapeutic target for pancreatic cancer.

21 June 2024 in iScience
Verified
Journal Article
Open access
STSui-Chih Tien
Sui-Chih Tien
CCChin-Chun Chang
Chin-Chun Chang
CHChing-Hsuan Huang
Ching-Hsuan Huang
HPHsuan-Yu Peng
Hsuan-Yu Peng
YCYu-Ting Chang
Yu-Ting Chang
CHChun-Mei Hu
Chun-Mei Hu
Over 80% of the patients with pancreatic ductal adenocarcinoma (PDAC) have cachexia/wasting syndrome. Cachexia is associated with reduced survival, decreased quality of life, and higher metastasis rates. Here, we demonstrate that fat loss is the earliest feature of PDAC-exosome-induced cachexia. MicroRNA sequencing of exosomal components from normal and cancer-derived exosomes revealed enrichment of miR-16-5p, miR-21-5p, miR-29a-3p, and miR-125b-5p in serum exosomes of mice harboring PDAC and patients with PDAC. Further, miR-16-5p and miR-29a-3p inhibited adipogenesis through decreasing Erlin2 and Cmpk1 expression which downregulates C/EBPβ and PPARγ. Synergistically, miR-29a-3p promotes lipolysis through increasing ATGL expression by suppressing MCT1 expression. Furthermore, PDAC-exosomes deprived of miR-16-5p and miR-29a-3p fail to induce fat loss. Hence, miR-16-5p and miR-29a-3p exosomal miRs are essential for PDAC-induced fat loss. Thus, we unravel that PDAC induces adipose atrophy via exosomal miRs. This knowledge may provide new diagnostic and therapeutic strategies for PDAC-induced cachexia.